BioPharma« Terug naar discussie overzicht

quote:

Omnius schreef op 12 juli 2016 11:12:

www.prnewswire.com/news-releases/immu...

The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

NPT kan beter de hele toko kopen voor 50 miljoen, eruit halen wat ze willen hebben en de rest doorverkopen.

quote:

Omnius schreef op 12 juli 2016 10:50:

had me nog niet echt hierin verdiept, maar zie dat ze een behoorlijke pijplijn hebben, en dat bij een marketcap van 20 milj. USD.

zie dat ze bezig zijn met een deal voor Amiket:
www.insiderfinancial.com/immune-pharm...

The highlight of the recent update was that IMNP executed an exclusive 60-day option with Novel Pain Therapeutics (“NPT”) to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

While the news is indeed positive, it’s still just a 60-day option and needs to be executed. That’s why shares ultimately sold off after the news was announced. The recent bounce has us thinking that the deal may be happening and some in the know are buying in anticipation of the option being executed. Shares also put in a triple bottom at $.20 per share and that signaled to momentum players to pile in and drive the shorts to cover their positions.

Dit is dus de reden van de stijging van de laatste weken? Hopelijk slepen ze er een goede deal uit, zodat de cashproblemen opgelost zijn.

quote:

greenways schreef op 12 juli 2016 13:10:

.53 nu, laat maar lekker gaan zo.
Succes allen.

quote:

Omnius schreef op 13 juli 2016 16:40:

minder dagje vandaag, misschien door deze headline (die toch al bekend was?):
www.journaltranscript.com/2016/07/imm...

The NASDAQ has granted Immune Pharmaceuticals Inc (NASDAQ:IMNP) an additional 180 calendar days, to regain compliance with the Listing Rule 5810(c) (3). Under the rule, companies are expected to ensure their stock trades above the $1 a share mark, in the market. That has not been the case for the pharmaceutical company, which was handed its first warning at the start of the year.

Should the company fail to comply by, January 3, 2017, it faces a possible delisting from the NASDAQ Capital Market.

Patent Application

Meanwhile, the clinical stage biopharmaceutical company has filed a patent application for the combination of AZIXA and Immune checkpoint inhibitors for the treatment of Cancer. The company on its filing says that the recent pre-clinical experiments have proved beyond doubt that the combination can cause improved tumor response.

Chief executive officer, Dr. Daniel Teper, says that such combination treatments have the potential to augment response to immune checkpoint inhibitors. The executive expects the recent data to open up new potential strategic options, given that Azixa has already demonstrated pre-clinical trial and clinical activity in multiple tumor types.

Expansion of Bertilimumab Phase II Trial

Separately, Immune has confirmed the expansion of its Bertilimumab Phase II clinical trial to include six new clinical sites in the United States. The company has already received IRB approval for the use of the anti-eotaxin monoclonal antibody for the treatment of bullous pemphigoid.

Bertilimumab bills itself as a first class anti-eotaxin able to block eotaxin-1, which is a key driver of the condition. Common in old people, the disease manifests itself with the blistering of the skin. There are currently about 60,000 people in the US and Europe struggling with the condition

Some of the new sites where Immune Pharmaceuticals Inc (NASDAQ:IMNP) will carry out the trials include the, University Hospitals Cleveland Medical Center, Mount Sinai in New York, Duke University, the University of Iowa, the University of Buffalo, and the University of Utah.

quote:

Omnius schreef op 14 juli 2016 09:33:

Is er nieuws?
In VS after hours + 10% en hier -10%.

quote:

surveyor schreef op 18 juli 2016 13:04:

Bam bio rommel 130% plus ;).

m.nasdaq.com/symbol/imnp

Nu alleen nog volume ;)

quote:

Omnius schreef op 18 juli 2016 13:11:

[...]

op 14 stuks, ik geniet er nog maar even van totdat de beurs opengaat ;-)